Arlene Odelia Siefker-Radtke

Professor

  • 5337 Citations
  • 39 h-Index
1992 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Arlene Odelia Siefker-Radtke is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Urinary Bladder Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Cystectomy Medicine & Life Sciences
Urinary Bladder Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Cisplatin Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2019

5 Citations (Scopus)

Erdafitinib in locally advanced or metastatic urothelial carcinoma

Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh, A., Mellado, B., Varlamov, S., Joshi, M., Duran, I., Tagawa, S. T., Zakharia, Y., Zhong, B., Stuyckens, K., Santiago-Walker, A., De Porre, P., O'Hagan, A., Avadhani, A. & 1 others, Siefker-Radtke, A. O., Jul 25 2019, In : New England Journal of Medicine. 381, 4, p. 338-348 11 p.

Research output: Contribution to journalArticle

Carcinoma
Fibroblast Growth Factor Receptors
Immunotherapy
Disease-Free Survival
Therapeutics
1 Citation (Scopus)

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer(Figure presented.)

Wang, L., Gong, Y., Saci, A., Szabo, P. M., Martini, A., Necchi, A., Siefker-Radtke, A. O., Pal, S., Plimack, E. R., Sfakianos, J. P., Bhardwaj, N., Horowitz, A., Farkas, A. M., Mulholland, D., Fischer, B. S., Oh, W. K., Sharma, P., Zhu, J. & Galsky, M. D., Nov 1 2019, In : European urology. 76, 5, p. 599-603 5 p.

Research output: Contribution to journalArticle

Receptor, Fibroblast Growth Factor, Type 3
Neoplasms
Mutation
T-Lymphocytes
Immunotherapy
3 Citations (Scopus)

Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results

Sharma, P., Siefker-Radtke, A. O., de Braud, F., Basso, U., Calvo, E., Bono, P., Morse, M. A., Ascierto, P. A., Lopez-Martin, J., Brossart, P., Rohrberg, K., Mellado, B., Fischer, B. S., Meadows-Shropshire, S., Saci, A., Callahan, M. K. & Rosenberg, J., Jan 1 2019, In : Journal of Clinical Oncology. 37, 19, p. 1608-1616 9 p.

Research output: Contribution to journalArticle

Carcinoma
Platinum
Immunotherapy
Multicenter Studies
Disease Progression

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses

Ohyama, C., Kojima, T., Kondo, T., Naya, Y., Inoue, T., Tomita, Y., Eto, M., Hisasue, S., Uemura, H., Obara, W., Kikuchi, E., Sharma, P., Galsky, M. D., Siefker-Radtke, A. O., Grossfeld, G., Collette, S., Gooden, K. & Kimura, G., Sep 13 2019, In : International Journal of Clinical Oncology. 24, 9, p. 1089-1098 10 p.

Research output: Contribution to journalArticle

Carcinoma
Population
Advisory Committees
Confidence Intervals
Safety

Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma

Duplisea, J. J., Petros, F. G., Li, R., Fellman, B., Guo, C. C., Czerniak, B. A., Siefker-Radtke, A. O., Araujo, J. C., Dinney, C. P. & Matin, S., Jun 1 2019, In : Urologic Oncology: Seminars and Original Investigations. 37, 6, p. 354.e19-354.e26

Research output: Contribution to journalArticle

Carcinoma
Neoplasms
Adjuvant Chemotherapy
Drug Therapy
Survival